Literature DB >> 15795304

Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses.

Xiaolin Wu1, Yuan Li, Bruce Crise, Shawn M Burgess, David J Munroe.   

Abstract

Integration into the host genome is one of the hallmarks of the retroviral life cycle and is catalyzed by virus-encoded integrases. While integrase has strict sequence requirements for the viral DNA ends, target site sequences have been shown to be very diverse. We carefully examined a large number of integration target site sequences from several retroviruses, including human immunodeficiency virus type 1, simian immunodeficiency virus, murine leukemia virus, and avian sarcoma-leukosis virus, and found that a statistical palindromic consensus, centered on the virus-specific duplicated target site sequence, was a common feature at integration target sites for these retroviruses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795304      PMCID: PMC1069554          DOI: 10.1128/JVI.79.8.5211-5214.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

Review 1.  Targeting survival: integration site selection by retroviruses and LTR-retrotransposons.

Authors:  Frederic D Bushman
Journal:  Cell       Date:  2003-10-17       Impact factor: 41.582

2.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

3.  Nucleosomes, DNA-binding proteins, and DNA sequence modulate retroviral integration target site selection.

Authors:  P M Pryciak; H E Varmus
Journal:  Cell       Date:  1992-05-29       Impact factor: 41.582

Review 4.  Integration target site selection for retroviruses and transposable elements.

Authors:  X Wu; S M Burgess
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

5.  Integrase-specific enhancement and suppression of retroviral DNA integration by compacted chromatin structure in vitro.

Authors:  Konstantin D Taganov; Isabel Cuesta; René Daniel; Lisa Ann Cirillo; Richard A Katz; Kenneth S Zaret; Anna Marie Skalka
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Genome-wide analyses of avian sarcoma virus integration sites.

Authors:  Anna Narezkina; Konstantin D Taganov; Samuel Litwin; Radka Stoyanova; Junpei Hayashi; Christoph Seeger; Anna Marie Skalka; Richard A Katz
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

8.  Insertion site preferences of the P transposable element in Drosophila melanogaster.

Authors:  G C Liao; E J Rehm; G M Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

9.  Retroviral integration into minichromosomes in vitro.

Authors:  P M Pryciak; A Sil; H E Varmus
Journal:  EMBO J       Date:  1992-01       Impact factor: 11.598

10.  Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.

Authors:  Rick S Mitchell; Brett F Beitzel; Astrid R W Schroder; Paul Shinn; Huaming Chen; Charles C Berry; Joseph R Ecker; Frederic D Bushman
Journal:  PLoS Biol       Date:  2004-08-17       Impact factor: 8.029

View more
  94 in total

Review 1.  HIV DNA integration.

Authors:  Robert Craigie; Frederic D Bushman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

2.  DNA pattern recognition using canonical correlation algorithm.

Authors:  B K Sarkar; Chiranjib Chakraborty
Journal:  J Biosci       Date:  2015-10       Impact factor: 1.826

3.  Retrotransposon suicide: formation of Ty1 circles and autointegration via a central DNA flap.

Authors:  David J Garfinkel; Karen M Stefanisko; Katherine M Nyswaner; Sharon P Moore; Jangsuk Oh; Stephen H Hughes
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

4.  HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications.

Authors:  Gary P Wang; Angela Ciuffi; Jeremy Leipzig; Charles C Berry; Frederic D Bushman
Journal:  Genome Res       Date:  2007-06-01       Impact factor: 9.043

Review 5.  Integrase, LEDGF/p75 and HIV replication.

Authors:  E M Poeschla
Journal:  Cell Mol Life Sci       Date:  2008-05       Impact factor: 9.261

6.  Biochemical and biophysical analyses of concerted (U5/U3) integration.

Authors:  Duane P Grandgenett; Sibes Bera; Krishan K Pandey; Ajaykumar C Vora; Jacob Zahm; Sapna Sinha
Journal:  Methods       Date:  2008-11-29       Impact factor: 3.608

7.  Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.

Authors:  Gary P Wang; Bruce L Levine; Gwendolyn K Binder; Charles C Berry; Nirav Malani; Gary McGarrity; Pablo Tebas; Carl H June; Frederic D Bushman
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

8.  Sleeping beauty transposition from nonintegrating lentivirus.

Authors:  Conrad A Vink; H Bobby Gaspar; Richard Gabriel; Manfred Schmidt; R Scott McIvor; Adrian J Thrasher; Waseem Qasim
Journal:  Mol Ther       Date:  2009-05-05       Impact factor: 11.454

Review 9.  Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Authors:  René Daniel; Johanna A Smith
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

10.  Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration.

Authors:  Yasuhiro Koh; Xiaolin Wu; Andrea L Ferris; Kenneth A Matreyek; Steven J Smith; KyeongEun Lee; Vineet N KewalRamani; Stephen H Hughes; Alan Engelman
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.